Drug treatment of schizophrenia: Myths and realities

J. Gerlach, Daniel Casey

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The most notable research in drug treatment of schizophrenia this decade has been concerned with the identification of different receptor subtypes in the brain and the attempts to relate antipsychotic effects of novel antipsychotics to the blockade of subgroups and combinations of these receptors. At the same time, more pragmatic clinical research approaches have tried to improve our abilities to use available antipsychotics (by means of different dose strategies, plasma drug monitoring etc.), and to evaluate the therapeutic effect, not only in positive and negative symptoms, but also in cognitive function, subjective feelings and quality of life. In this research area, some myths and other critical aspects have evolved to powerfully influence the field.

Original languageEnglish (US)
Pages (from-to)65-70
Number of pages6
JournalCurrent Opinion in Psychiatry
Volume7
Issue number1
StatePublished - 1994
Externally publishedYes

Fingerprint

Antipsychotic Agents
Schizophrenia
Research
Pharmaceutical Preparations
Aptitude
Drug Monitoring
Therapeutic Uses
Cognition
Emotions
Quality of Life
Brain

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Drug treatment of schizophrenia : Myths and realities. / Gerlach, J.; Casey, Daniel.

In: Current Opinion in Psychiatry, Vol. 7, No. 1, 1994, p. 65-70.

Research output: Contribution to journalArticle

Gerlach, J & Casey, D 1994, 'Drug treatment of schizophrenia: Myths and realities', Current Opinion in Psychiatry, vol. 7, no. 1, pp. 65-70.
Gerlach, J. ; Casey, Daniel. / Drug treatment of schizophrenia : Myths and realities. In: Current Opinion in Psychiatry. 1994 ; Vol. 7, No. 1. pp. 65-70.
@article{ffc5df1400624068b1a2e85f7a329fd3,
title = "Drug treatment of schizophrenia: Myths and realities",
abstract = "The most notable research in drug treatment of schizophrenia this decade has been concerned with the identification of different receptor subtypes in the brain and the attempts to relate antipsychotic effects of novel antipsychotics to the blockade of subgroups and combinations of these receptors. At the same time, more pragmatic clinical research approaches have tried to improve our abilities to use available antipsychotics (by means of different dose strategies, plasma drug monitoring etc.), and to evaluate the therapeutic effect, not only in positive and negative symptoms, but also in cognitive function, subjective feelings and quality of life. In this research area, some myths and other critical aspects have evolved to powerfully influence the field.",
author = "J. Gerlach and Daniel Casey",
year = "1994",
language = "English (US)",
volume = "7",
pages = "65--70",
journal = "Current Opinion in Psychiatry",
issn = "0951-7367",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Drug treatment of schizophrenia

T2 - Myths and realities

AU - Gerlach, J.

AU - Casey, Daniel

PY - 1994

Y1 - 1994

N2 - The most notable research in drug treatment of schizophrenia this decade has been concerned with the identification of different receptor subtypes in the brain and the attempts to relate antipsychotic effects of novel antipsychotics to the blockade of subgroups and combinations of these receptors. At the same time, more pragmatic clinical research approaches have tried to improve our abilities to use available antipsychotics (by means of different dose strategies, plasma drug monitoring etc.), and to evaluate the therapeutic effect, not only in positive and negative symptoms, but also in cognitive function, subjective feelings and quality of life. In this research area, some myths and other critical aspects have evolved to powerfully influence the field.

AB - The most notable research in drug treatment of schizophrenia this decade has been concerned with the identification of different receptor subtypes in the brain and the attempts to relate antipsychotic effects of novel antipsychotics to the blockade of subgroups and combinations of these receptors. At the same time, more pragmatic clinical research approaches have tried to improve our abilities to use available antipsychotics (by means of different dose strategies, plasma drug monitoring etc.), and to evaluate the therapeutic effect, not only in positive and negative symptoms, but also in cognitive function, subjective feelings and quality of life. In this research area, some myths and other critical aspects have evolved to powerfully influence the field.

UR - http://www.scopus.com/inward/record.url?scp=0028029107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028029107&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028029107

VL - 7

SP - 65

EP - 70

JO - Current Opinion in Psychiatry

JF - Current Opinion in Psychiatry

SN - 0951-7367

IS - 1

ER -